Literature DB >> 7129525

Monoclonal antibodies to rat sarcomata. I. Immunization procedures and source of lymphoid cells for hybridoma production.

S M North, J M Styles, S M Hobbs, C J Dean.   

Abstract

Hybridomas secreting monoclonal antibodies with specificity for Hooded rat fibrosarcomata have been obtained by fusion of the rat myeloma Y3 Ag 1.2.3. (Galfre, Milstein & Wright, 1979) with cells taken from spleens or lymph nodes of immunized syngeneic and allogeneic donors. Two of the monoclonal antibodies, both derived from he spleens of tumour bearers, showed specificity for individual tumours one for MC24 (M10/76) and the other for HSNTC (11/160). These two antibodies had a long half-life in the blood when injected intravenously showing that they had a low affinity for normal tissue antigens. Monoclonal antibodies exhibiting broad tumour specificity or extensive cross-reactivity with normal cells were secreted by many of the hybridomas derived from both syngeneic and allogeneic rats that had been hyperimmunized with tumour cells. These results are discussed in relation to the production of monoclonal anti-tumour antibodies for use in experimental therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7129525      PMCID: PMC1555540     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Occurrence of specific antibodies of the IgA class in the bile of rats.

Authors:  J Hall; E Orlans; J Reynolds; C Dean; J Peppard; L Gyure; S Hobbs
Journal:  Int Arch Allergy Appl Immunol       Date:  1979

Review 2.  Patterns of gene expression and the cellular origins of human leukaemias.

Authors:  M Greaves; G Janossy
Journal:  Biochim Biophys Acta       Date:  1978-10-27

3.  Macrophage content of tumours in relation to metastatic spread and host immune reaction.

Authors:  S A Eccles; P Alexander
Journal:  Nature       Date:  1974-08-23       Impact factor: 49.962

4.  Tumour-specific antibody neutralization of factors in rat hepatoma-bearer serum which abrogate lymph-node-cell cytotoxicity.

Authors:  R A Robins; R W Baldwin
Journal:  Int J Cancer       Date:  1974-11-15       Impact factor: 7.396

5.  The glomerular permeability determined by dextran clearance using Sephadex gel filtration.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1968       Impact factor: 1.713

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG.

Authors:  G Galfrè; C Milstein; B Wright
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

8.  Tumour-specific complement-dependent serum cytotoxicity against a chemically induced rat hepatoma.

Authors:  M R Price; R W Baldwin
Journal:  Int J Cancer       Date:  1977-08-15       Impact factor: 7.396

9.  The growth patterns of two transplantable acute leukaemias of spontaneous origin in rats.

Authors:  A B Wrathmell
Journal:  Br J Cancer       Date:  1976-02       Impact factor: 7.640

10.  Influence of tumour growth on the evolution of cytotoxic lymphoid cells in rats bearing a spontaneously metastasizing syngeneic fibrosarcoma.

Authors:  G A Currie; J O Gage
Journal:  Br J Cancer       Date:  1973-08       Impact factor: 7.640

View more
  10 in total

1.  Pharmacokinetic studies of radiolabelled rat monoclonal antibodies recognising syngeneic sarcoma antigens. I. Comparison of IgG subclasses.

Authors:  S A Eccles; H P Purvies; J M Styles; S M Hobbs; C J Dean
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Monoclonal antibodies to rat sarcomata. II. A syngeneic IgG2b antibody with anti-tumour activity.

Authors:  S M North; C J Dean
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

3.  Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge.

Authors:  P L Dunn; C A Johnson; J M Styles; S S Pease; C J Dean
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

4.  An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B chain.

Authors:  S A Eccles; D P McIntosh; H P Purvies; A J Cumber; G D Parnell; J A Forrester; J M Styles; C J Dean
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  The production of hybridomas from the gut associated lymphoid tissue of tumour bearing rats. II. Peripheral intestinal lymph as a source of IgA producing cells.

Authors:  J M Styles; C J Dean; L A Gyure; S M Hobbs; J G Hall
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

6.  The production of hybridomas from the gut associated lymphoid tissue of tumour bearing rats. I. Mesenteric nodes as a source of IgG producing cells.

Authors:  C J Dean; J M Styles; L A Gyure; J Peppard; S M Hobbs; E Jackson; J G Hall
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

7.  Rat serum antibodies binding to high-molecular-weight glycoprotein(s) on syngeneic colon carcinomas, demonstrated by competition with rat monoclonal antibody.

Authors:  B Jansson; T Brodin; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

8.  The shedding of viable cells into the local lymph by tumours growing in the gut of rats.

Authors:  L A Gyure; J M Styles; C J Dean; K Nagy; J G Hall
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

9.  Effect of host immune status on the spontaneous metastasis of cloned cell lines of the 13762NF rat mammary adenocarcinoma.

Authors:  S M North; G L Nicolson
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

10.  Immunity to a syngeneic sarcoma induced in rats by dendritic lymph cells exposed to the tumour either in vivo or in vitro.

Authors:  L A Gyure; R Barfoot; S Denham; J G Hall
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.